You can buy or sell FPRX and other stocks, options, ETFs, and crypto commission-free!
Five Prime Therapeutics, Inc. Common Stock, also called Five Prime Therapeutics, is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. Read More The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Yahoo FinanceMay 8
Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 4.67% and -6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 8
Five Prime Therapeutics Reports First Quarter 2019 Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced its results for the first quarter and provided an update on the company’s recent activities. The company also provided an update on the Phase 3 FIGHT trial testing bemarituzumab in combination with mFOLFOX6 in patients with gastric (GC) or gastroesophageal junction (GEJ) cancer that...
Yahoo FinanceMay 7
See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.
Five Prime Therapeutics Inc NASDAQ/NGS:FPRX View full report here! Summary ETFs holding this stock are seeing positive inflows Bearish sentiment is moderate Economic output in this company's sector is expanding Bearish sentiment Short interest | Neutral Short interest is moderate for FPRX with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors...
Expected Aug 7, After Hours